- Home
- AMC vs NRIX Comparison
AMC vs NRIX Comparison
Compare AMC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMC | NRIX |
|---|---|---|
| Founded | 1920 | 2009 |
| Country | United States | United States |
| Employees | N/A | 357 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMC | NRIX |
|---|---|---|
| Price | $2.96 | $25.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $2.03 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 21.4M | 1.1M |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | $76,987,000.00 |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $5.18 | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.57 | ★ 99.31 |
| 52 Week Low | $0.93 | $8.20 |
| 52 Week High | $3.18 | $28.23 |
Technical Indicators
Market Signals| Indicator | AMC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 50.27 |
| Support Level | $2.34 | $24.61 |
| Resistance Level | N/A | $28.23 |
| Average True Range (ATR) | 0.15 | 1.02 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 92.33 | 49.72 |
Price Performance
Historical ComparisonAbout AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.